Q-omics provides the consensus-scored VPS35L profile across patient tissues and cancer cell-line models. VPS35L expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, VPS35L is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, VPS35L protein abundance shows 32,859 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, COAD, and LUAD as cancer lineages where VPS35L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VPS35L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VPS35L survival associations across molecular data types. VPS35L RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VPS35L RNA expression–survival associations across cancer types. High VPS35L expression shows unfavorable associations in BLCA and STAD, but favorable associations in KIRC, BRCA, KIRP and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for VPS35L RNA expression.
This table summarizes VPS35L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 11. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for VPS35L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VPS35L shows lower tumor expression in COAD, KICH and UCEC and higher tumor expression in KIRP, CHOL and BRCA. The COAD box plot shows higher VPS35L RNA expression in normal versus tumor tissue (log2 FC = −1.570, t-test p < 0.001).
This table shows molecular features associated with VPS35L in patient tissues and cancer cell lines. In patient samples, VPS35L shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, VPS35L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
